Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Present and future developments of antithrombotic agents].

G Montalescot1

  • 1Institut de cardiologie, Groupe hospitalier La Pitié-Salpêtrière, Paris.

Archives Des Maladies Du Coeur Et Des Vaisseaux
|March 24, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mass balance and metabolite profiling of <sup>14</sup>C-Zalunfiban in humans following single-dose subcutaneous administration.

Xenobiotica; the fate of foreign compounds in biological systems·2025
Same author

Zalunfiban at First Medical Contact for ST-Elevation Myocardial Infarction.

NEJM evidence·2025
Same author

Prognostic value of longitudinal strain and ejection fraction in Friedreich's ataxia.

International journal of cardiology·2021
Same author

Unusual arterial thrombotic events in Covid-19 patients.

International journal of cardiology·2020
Same author

Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry.

Annales de cardiologie et d'angeiologie·2020
Same author

[Coronary thrombosis: Physiopathology and treatment in the era of tailored medicine].

Annales de cardiologie et d'angeiologie·2017
Same journal

Radiokymographic study of the kinetics of the middle arc and the hils in the normal subject.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

A medication for angina pectoris and pre-fibrillatory conditions; 1262 F; six years of clinical experience; action mechanism.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

Circulatory changes following the injection of hypertonic saline solutions; application to the study of angina pectoris.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

Alterations in coronary circulation during aortic insufficiency in young subjects.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

Cardio-esophageal auscultation.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

Hypertensive accidents following the injection of acetylcholine.

Archives des maladies du coeur et des vaisseaux·2010
See all related articles

New antithrombotic strategies balance efficacy and bleeding risk in cardiology. Higher clopidogrel doses and novel agents like prasugrel show promise, alongside improved thrombin inhibitors for interventional procedures.

Area of Science:

  • Cardiology
  • Pharmacology

Context:

  • Interventional cardiology necessitates balancing antithrombotic efficacy with bleeding risk.
  • Development of novel antithrombotic agents and strategies is ongoing.
  • Existing agents like clopidogrel are being evaluated at higher dosages (600 mg, 900 mg) and long-term administration.

Purpose:

  • To review advancements in antithrombotic therapies for interventional cardiology.
  • To evaluate new antithrombotic agents and their clinical potential.
  • To discuss evolving administration strategies for improved patient outcomes.

Summary:

  • Higher doses of clopidogrel (600 mg, 900 mg) demonstrate improved biological effects warranting further clinical trials.
  • Newer thienopyridines, such as prasugrel, exhibit potent effects and have undergone large-scale clinical assessment.

Related Experiment Videos

  • Antiplatelet GPIIb/IIIa inhibitors are being reconsidered in new administration strategies.
  • Direct and indirect thrombin inhibitors are being developed to replace unfractionated heparin, offering more predictable activity.
  • Low molecular weight heparins provide easier administration compared to unfractionated heparin.
  • Synthetic factor Xa inhibitors are in early developmental stages.
  • Bivalirudine, a direct thrombin antagonist, offers an improved benefit/risk profile for catheter laboratory procedures.

    • Impact:

    • Novel antithrombotic agents and strategies may optimize the balance between preventing thrombosis and minimizing bleeding complications.
    • Bivalirudine presents a new, favorable option for anticoagulation during periprocedural care.
    • Ongoing research and clinical trials are crucial for validating the efficacy and safety of these emerging antithrombotic therapies.